Treatment of Intermediate‐Risk Hepatoblastoma Using a Combined Cisplatin and Doxorubicin (PLADO) Regimen and Optimized Surgical Resection
Open Access
- 9 May 2025
- journal article
- clinical trial
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (8) , e31770
Abstract
Background: Complete resection of the primary tumor is critical for the survival of children with hepatoblastomas (HBs). This prospective clinical study aimed to clarify the outcome of a chemotherapy regimen comprising cisplatin and doxorubicin (PLADO) followed by definitive surgery conducted at the appropriate time in patients with intermediate‐risk HB.Methods: Intermediate‐risk HB was defined as patients without evidence of metastatic disease who met any of the following criteria: age ≥3 years; PRETEXT IV disease; presence of more than one PRETEXT annotation factor. The study protocol consisted of four preoperative and two postoperative courses of PLADO. The appropriate surgeries were conducted at optimized timings via real‐time central surgical reviews.Results: The 3‐year progression‐free and overall survivals of the 33 intermediate‐risk patients included were 78.7% and 87.9%, respectively. Preoperative PLADO resulted in a partial response in 83.9% of the patients. Microscopic complete resection was ultimately obtained in 31 (94%) patients. No patient required more than six preoperative courses before surgery or liver transplantation (LTx). Two patients never had surgery due to tumor progression.Conclusions: The outcome for patients with intermediate‐risk HB was satisfactory. PLADO, combined with surgery (including LTx) conducted at the optimal time, appeared to cure most patients in this study.Keywords
All Related Versions
Funding Information
- Japan Agency for Medical Research and Development (JP17ck0106332, JP20ck0106609, JP20lk0201066)
- Japan Society for the Promotion of Science (JP16H02778)
This publication has 14 references indexed in Scilit:
- Doxorubicin in combination with cisplatin, 5‐flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group studyCancer, 2021
- Feasibility of dose‐dense cisplatin‐based chemotherapy in Japanese children with high‐risk hepatoblastoma: Analysis of the JPLT3‐H pilot studyPediatric Blood & Cancer, 2021
- Microscopically positive resection margin after hepatoblastoma resection: what is the impact on prognosis? A Childhood Liver Tumours Strategy Group (SIOPEL) reportEuropean Journal of Cancer, 2019
- Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing LossNew England Journal of Medicine, 2018
- Malignant tumors of the liver in childrenSeminars in Pediatric Surgery, 2016
- Hepatoblastoma clinical research: Lessons learned and future challengesPediatric Blood & Cancer, 2012
- Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk HepatoblastomaNew England Journal of Medicine, 2009
- Liver tumors: Pediatric populationLiver Transplantation, 2008
- Guidelines for surgical treatment of hepatoblastoma in the modern era – Recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL)European Journal of Cancer, 2005
- Risk-adapted treatment for childhood hepatoblastomaEuropean Journal of Cancer, 2004